Breast Cancer Loses Against New Drug Combination
A Northwestern University researcher has found that “when the leukemia drug dasatinib is combined with the breast cancer drug doxorubicin, the potent mix inhibits breast cancer cell invasion by half” according to Northwestern’s Health Science Editor Marla Paul.
The drug combo is aimed at preventing the spread of breast cancer to other organs. “Perhaps this drug could be given to prevent invasion from happening in the first place . . . This might keep the disease in check and prevent it from progressing.” according to Seth Cory, principle research investigator.
Comments are closed.